Methotrexate compared with apremilast for itching in people with psoriasis
Compares methotrexate and apremilast for itching and quality of life in psoriasis.
Plain-language title generated from the registry record
Registry title: Methotrexate Versus Apremilast for Pruritus in Psoriasis
Key facts
- Where
- Rawalpindi, PakistanSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07432386, who can take part
Where in Pakistan
- Pak Emirates Military HospitalRawalpindi, PakistanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Zarmeen Khawar
- Trial code
- NCT07432386
- Record updated
- 15 May 2026
- Original description
This randomized controlled trial aims to compare the efficacy of Methotrexate versus Apremilast in reducing pruritus and improving quality of life in patients with psoriasis. Eighty patients aged 20 to 60 years with psoriasis involving more than 8% body surface area and associated pruritus will be enrolled and randomly assigned into two groups. Group A will receive oral Apremilast titrated to 30 mg twice daily, while Group B will receive oral Methotrexate 10 mg once weekly for 8 weeks. The primary outcome will be change in Dermatology Life Quality Index (DLQI) score at 8 weeks. Secondary outcomes include change in numerical rating scale for pruritus and assessment of adverse effects. The study will be conducted at Pakistan Emirates Military Hospital Rawalpindi.Read full original descriptionShow less
Comparison of Efficacy of Methotrexate Versus Apremilast in the Treatment of Pruritus in Psoriasis: A Randomized Controlled Trial
This randomized controlled trial aims to compare the efficacy of Methotrexate versus Apremilast in reducing pruritus and improving quality of life in patients with psoriasis. Eighty patients aged 20 to 60 years with psoriasis involving more than 8% body surface area and associated pruritus will be enrolled and randomly assigned into two groups. Group A will receive oral Apremilast titrated to 30 mg twice daily, while Group B will receive oral Methotrexate 10 mg once weekly for 8 weeks. The primary outcome will be change in Dermatology Life Quality Index (DLQI) score at 8 weeks. Secondary outcomes include change in numerical rating scale for pruritus and assessment of adverse effects. The study will be conducted at Pakistan Emirates Military Hospital Rawalpindi.
Inclusion: Male and female patients aged 18 to 65 years; Clinically diagnosed cases of psoriasis; Patients experiencing pruritus associated with psoriasis; Patients willing to participate and provide written informed consent; Patients able to comply with study protocol and follow-up visits.
Exclusion: Patients currently receiving systemic therapy for psoriasis within the last 4 weeks; Patients with severe hepatic or renal impairment; Patients with known hypersensitivity to Methotrexate or Apremilast; Patients with active infections, including tuberculosis; Patients with malignancy; - Pregnant or lactating women; Patients with significant hematological abnormalities; Patients unwilling to provide informed consent.